Wall Street analyst estimates for AbbVie Inc. (ABBV): consensus price target, buy/hold/sell recommendations and forecasts for revenue and EPS for the upcoming fiscal years.
AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet's diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active...
Consensus price target
$294.00 (-0 % vs price $294.89)
between $235.00 and $325.00 · 12 targets published in the last quarter
Closing price, Oct 30
A twelve-month target is not a fair value: compare it with the range in the Valuation tab.
Revenue and EPS estimates
| Fiscal year | Revenue (average) | Revenue (low – high) | EPS (average) | Analysts |
|---|---|---|---|---|
| 2026E | $67.6B | $67.5B – $68.0B | $13.94 | 12 |
| 2027E | $73.6B | $71.9B – $75.0B | $16.26 | 15 |
| 2028E | $79.3B | $75.6B – $82.1B | $17.99 | 8 |
Figures in USD · consensus as of November 1, 2026
Analyst Consensus
| Strong Buy | 0 |
| Buy | 32 |
| Hold | 11 |
| Sell | 1 |
| Strong Sell | 0 |
| Total analysts | 44 |
| Avg rating (−2 sell to +2 buy) | 0.70 |
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2027-02-03 | $3.90 | ||
| 2026-10-30 | $3.82 | $3.73 | +2.4% |
| 2026-07-31 | $3.65 | $3.61 | +1.1% |
| 2026-04-29 | $2.65 | $2.59 | +2.3% |
| 2026-02-04 | $2.71 | $2.65 | +2.3% |
| 2025-10-31 | $1.86 | $1.77 | +5.1% |
| 2025-07-31 | $2.97 | $2.88 | +3.1% |
| 2025-04-25 | $2.46 | $2.38 | +3.4% |
Valuation Ratios
| P/E Ratio | 83.08 |
| Price / Book | -88.04 |
| Dividend Yield | 2.35% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $25.64B | $28.22B | $32.75B | $33.27B | $45.80B | $56.20B | $58.05B | $54.32B | $56.33B | $61.16B |
| Cost of Revenue | $5.83B | $7.04B | $7.72B | $7.44B | $15.39B | $17.45B | $17.41B | $20.41B | $16.90B | $18.20B |
| Gross Profit | $19.80B | $21.18B | $25.04B | $25.83B | $30.42B | $38.75B | $40.64B | $33.90B | $39.43B | $42.96B |
| Research & Development | $4.58B | $5.33B | $10.75B | $6.79B | $7.75B | $8.05B | $6.51B | $7.67B | $12.79B | $9.10B |
| Selling, General & Admin | $5.88B | $6.29B | $7.40B | $6.94B | $11.30B | $12.35B | $15.26B | $12.87B | $14.75B | $14.01B |
| Operating Expenses | $10.47B | $11.63B | $18.65B | $12.84B | $19.05B | $20.83B | $22.52B | $21.15B | $30.29B | $22.86B |
| Operating Income | $9.34B | $9.54B | $6.38B | $12.98B | $11.36B | $17.92B | $18.12B | $12.76B | $9.14B | $20.09B |
| EBITDA | $10.12B | $10.38B | $8.31B | $12.23B | $12.32B | $23.93B | $24.17B | $17.17B | $14.91B | $17.63B |
| Interest Expense | $1.05B | $1.15B | $1.35B | $1.78B | $2.45B | $2.42B | $2.23B | $2.22B | $2.81B | $2.89B |
| Pre-tax Income | $7.88B | $7.73B | $5.20B | $8.43B | $3.40B | $12.99B | $13.48B | $6.25B | $3.72B | $6.60B |
| Income Tax | $1.93B | $2.42B | -$490.0M | $544.0M | -$1.22B | $1.44B | $1.63B | $1.38B | -$570.0M | $2.36B |
| Net Income | $5.95B | $5.31B | $5.69B | $7.88B | $4.62B | $11.54B | $11.84B | $4.86B | $4.28B | $4.23B |
| EPS | $3.65 | $3.31 | $3.69 | $5.30 | $2.73 | $6.48 | $6.65 | $2.73 | $2.40 | $2.37 |
| EPS (Diluted) | $3.63 | $3.30 | $3.68 | $5.28 | $2.72 | $6.45 | $6.63 | $2.72 | $2.39 | $2.37 |
| Shares Outstanding (Diluted) | 1,631.0 M | 1,603.0 M | 1,546.0 M | 1,484.0 M | 1,673.0 M | 1,777.0 M | 1,778.0 M | 1,773.0 M | 1,773.0 M | 1,774.0 M |
Price
| Price | $294.89 (closing price, October 30, 2026) |
| Market Cap | $521.1B |
| Exchange | NYSE |
| Country | US |
Related companies: MRK · AMGN · LLY · JNJ · AZN · NVS · PFE · BMY
Explore sector: Healthcare · Drug Manufacturers - General
More sections of ABBV: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method · Companies that pass the Lynch method · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks